2021
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchConceptsHepatic decompensationPortal hypertensionEvents of decompensationHepatic decompensation eventsLiver-related deathSignificant portal hypertensionAcceptable safety profileProspective human studiesRole of statinsChronic liver diseaseClasses of medicationsPatient-reported outcomesDevelopment of decompensationEffect of simvastatinVA Medical CenterCompensated cirrhosisDecompensation eventsStatin therapyVariceal hemorrhageCirrhotic patientsStandard therapyVascular reactivityExert pleiotropic effectsLiver diseaseRetrospective study
2017
Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States
Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.Peer-Reviewed Original ResearchConceptsMultivariable generalized linear modelsMultidisciplinary tumor boardHepatocellular carcinomaIntegrated health systemCancer-related costsHealthcare costsLiver transplantationBCLC stageLiver diseaseTumor boardBarcelona Clinic Liver Cancer stageVeterans Affairs Corporate Data WarehouseHealth systemCases of HCCBasis of receiptLiver disease cohortReceipt of transplantationLiver disease etiologyChronic liver diseaseLiver Cancer stageLiver cancer surveillanceBasis of severityHospital academic affiliationCorporate Data WarehouseCirrhosis controlsUp-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost.
Kaplan D, Yu S, Taddei T, Reiss K, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. Journal Of Clinical Oncology 2017, 35: 385-385. DOI: 10.1200/jco.2017.35.4_suppl.385.Peer-Reviewed Original ResearchDuration of exposureBCLC BICD9 codesBarcelona Clinic Liver Cancer stageInitiation of sorafenibMedian overall survivalLiver Cancer stageLonger exposure durationECOG PSExposure durationUp-titrationChild-TurcotteMELD scoreSorafenib therapyFirst doseOverall survivalPharmacy recordsMedian agePrescription fillsLiver diseaseTumor numberC-HCCEquivalent survivalHCC patientsCancer stageSorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival.
Kaplan D, Taddei T, Mehta R, D'Addeo K, Aytaman A, Hunt K, Fox R, Baytarian M, Valdarrama A. Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. Journal Of Clinical Oncology 2017, 35: 404-404. DOI: 10.1200/jco.2017.35.4_suppl.404.Peer-Reviewed Original ResearchICD9 codesBarcelona Clinic Liver Cancer stageOverall median survival rateInitial dosing regimensLiver Cancer stageMedian survival rateSimilar treatment durationCTP AECOG PSExtrahepatic spreadChild-TurcotteMacrovascular invasionMELD scorePrescriber specialtyReal-world practiceMedian agePharmacy recordsSorafenib exposureBCLC 0Dosing regimensLiver diseaseTumor numberPrescribing practicesHCC patientsCancer stage